ORMD-0801 QD

DRUG2 trials

Sponsors

Oramed, Ltd.

Conditions

Nonalcoholic Steatohepatitis (NASH)Type 2 Diabetes Mellitus

Phase 2

A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)

CompletedNCT04616014

Oramed, Ltd.Nonalcoholic Steatohepatitis (NASH)

Start: 2021-03-01End: 2022-09-15Updated: 2024-03-29

Phase 3

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

TerminatedNCT04606576

Oramed, Ltd.Type 2 Diabetes Mellitus

Start: 2020-12-15End: 2023-01-13Updated: 2023-02-09